Francois Nader, M.d., To Join Noven’s Board of Directors

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that Francois Nader, M.D., will join Noven’s Board of Directors effective May 22, 2009, immediately following the company’s Annual Meeting of Stockholders.

Dr. Nader has nearly 30 years of pharmaceutical industry experience in senior scientific, operational and strategic leadership roles. He is currently president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders. Previously, he served NPS as chief operating officer, chief medical officer and chief commercial officer.

Prior to NPS, Dr. Nader was chief medical officer and a venture partner at Care Capital, a life sciences venture capital firm with a substantial portfolio of specialty pharmaceutical and biotechnology investments. Prior to that, for 14 years he served Sanofi-Aventis Pharmaceuticals in a range of senior leadership roles in clinical, regulatory and medical affairs, healthcare marketing, managed care and global health economics. Earlier, he was head of global commercial operations for the Pasteur Vaccines division of Rhone-Poulenc.

Dr. Nader holds a doctorate in medicine from St. Joseph University in France, a master’s degree in medical marketing from Ecole Superieure de Commerce de Paris, and a master of business administration from the University of Tennessee.

Dr. Nader’s appointment will follow the retirement of Sidney Braginsky from the Noven Board. Mr. Braginsky announced in March 2009 that, after 17 years of service to Noven, he will not stand for re-election at the May 22 Stockholders’ Meeting. It is expected that Dr. Nader will succeed Mr. Braginsky as a member of Noven’s Audit Committee.

“We thank Sid Braginsky for his years of service and counsel to the company, and welcome the scientific and industry insights that Dr. Nader will bring to the Noven Board,” said Wayne P. Yetter, Chairman of Noven’s Board of Directors. “In particular, Francois’ substantial clinical, regulatory and medical expertise across a broad range of therapeutic categories, including women’s health and central nervous system disorders, should help Noven advance its product development pipeline and move closer to its goal of high growth in specialty pharmaceuticals.”

Because Dr. Nader was not identified as a director nominee prior to the mailing of the company’s 2009 proxy materials, he is not among the individuals nominated for election at the upcoming Stockholders’ Meeting. Accordingly, his appointment to the Board and to the Audit Committee will be effective immediately after the meeting.

Concurrent with this announcement, Noven issued a press release announcing that it had entered into a definitive merger agreement with Hisamitsu Pharmaceutical Co., Inc. That press release is available at

About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne Pharmaceuticals joint venture, and Noven Therapeutics, Noven’s specialty pharmaceutical marketing and sales unit. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. For more information, visit

Joseph C. Jones
Vice President – Corporate Affairs